Yi Wang1, Li Wang2. 1. Department of Neurosurgery, Cangzhou Central Hospital, Cangzhou, 061000, China. 2. Department of Oncology, The Third Affiliated Hospital of Hebei Medical University, 139 Xinyan Road, Shijiazhuang City, 050051, Hebei Province, China. liuliu_up@163.com.
Abstract
OBJECTIVE: To investigate the roles of miR-34a in progression and chemoresistance of glioma cells. RESULTS: Quantitative real-time PCR analysis showed that miR-34a level was lower, but PD-L1 expression level was higher in glioma tissue specimens compared with normal brain tissues and their expression levels were negatively correlated. Ectopic expression of miR-34a inhibited glioma cell proliferation, promoted cell cycle arrest in G1/S phase and cell apoptosis. Additionally, miR-34a/PD-L1 axis was again confirmed and co-expression of PD-L1 with miR-34a mimics attenuated the effects of miR-34a on cell proliferation and apoptosis in glioma cells. Importantly, PD-L1 overexpression resulted in chemoresistance in glioma cells, this effect was attenuated by miR-34a overexpression. CONCLUSIONS: miR-34a inhibits glioma cells progression and chemoresistance via targeting PD-L1.
OBJECTIVE: To investigate the roles of miR-34a in progression and chemoresistance of glioma cells. RESULTS: Quantitative real-time PCR analysis showed that miR-34a level was lower, but PD-L1 expression level was higher in glioma tissue specimens compared with normal brain tissues and their expression levels were negatively correlated. Ectopic expression of miR-34a inhibited glioma cell proliferation, promoted cell cycle arrest in G1/S phase and cell apoptosis. Additionally, miR-34a/PD-L1 axis was again confirmed and co-expression of PD-L1 with miR-34a mimics attenuated the effects of miR-34a on cell proliferation and apoptosis in glioma cells. Importantly, PD-L1 overexpression resulted in chemoresistance in glioma cells, this effect was attenuated by miR-34a overexpression. CONCLUSIONS:miR-34a inhibits glioma cells progression and chemoresistance via targeting PD-L1.
Entities:
Keywords:
Drug resistance; Glioma; PD-L1; Paclitaxel; miR-34a